Bacteria Link to Alzheimer's Gets Big Funding | San Jose News

Lighthouse Pharmaceuticals, based at the Buck Institute, is revolutionizing Alzheimer’s research with a bold new theory: gum disease bacteria P. gingivalis may be driving cognitive decline. Backed by a $49.2M NIH grant and a $500K investment from Marin Sonoma Impact Ventures, they’re launching a nationwide trial testing a daily pill to target this bacteria in 300 patients with mild to moderate Alzheimer’s. Early science shows the bacteria can migrate to the brain and impair memory—potentially affecting up to 40% of Alzheimer’s patients. With a $12M funding round and active recruitment, this startup is turning a dental bug into a brain-saving breakthrough—while boosting the North Bay’s innovation economy. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/958f2c581b1439d6